What Neuro20 Technologies does

Neuro20 Technologies Corp., founded in 2021 and headquartered at 140 Pine Ave N, Oldsmar, Florida, develops and sells the FDA-cleared Neuro20 PRO System, a Class II whole-body electrophysiological neuromodulation platform. The system comprises a wearable Smart Suit with 20 contoured electrodes, a battery-powered control box, and tablet-based software delivering 4 main programs and 9 additional modes capable of recruiting up to 42 muscles simultaneously and emulating sequenced motor chains. The company has built proprietary scientific frameworks - MEEPS (Mass External Electro-Physiological Signaling) and Cronilectric Theory - to position its technology around the Muscle-Neuro Axis rather than the isolated-muscle paradigm typical of conventional EMS devices, with the Chief Medical Officer holding 12 issued US patents in neuromuscular and cranial stimulation.

The company serves patients with neurological and musculoskeletal conditions - including multiple sclerosis, Long Covid, stroke, Parkinson's, spinal cord injury, traumatic brain injury, chronic pain, and orthopedic recovery - alongside athletic performance use cases. Its go-to-market is hybrid: a provider network of trained-and-approved practitioners (with a public "Find a Provider" directory across multiple US states) sells systems to clinics, while a direct-to-consumer motion sells the Home Care Unit to patients continuing therapy at home. Revenue is hardware-dominant, with the Smart Suit positioned as a 6-month consumable replacement item and software updates bundled into the system; pricing is quote-based and not publicly disclosed. A UK subsidiary, Neuro20 Technologies UK Ltd., supports European GDPR compliance. The company is founder-owned, with no institutional funding rounds disclosed in source material, and is operated by a team of 1-10 employees.

Clinical validation is anchored in research partnerships with 8 of the top 25 US rehabilitation hospitals and pilot programs at institutions such as the University of Tampa Human Performance Lab. Leadership combines commercial operators with deep clinical credibility, including a CMO who founded the Yale School of Medicine neuro-rehabilitation program, a Director of Science with a PhD from Columbia/Caltech, and DPT-level clinical leadership publishing the first position paper on Whole Body Electrical Stimulation with Long Covid patients in 2024.

Name

Neuro20 Technologies

Legal name

Neuro20 Technologies Corp.

Website

https://neuro20.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

1–10 employees

Short description

Neuro20 Technologies, founded in 2021 and based in Oldsmar, Florida, markets the FDA-cleared Neuro20 PRO System, a whole-body wearable electrical muscle stimulation platform serving patients with neurological, orthopedic, and chronic pain conditions via certified healthcare providers and a direct-to-consumer home unit.

Ownership category

akta.pro rank

Headquarters

HQ city

Oldsmar

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Hardware Sales - Neuro20 PRO System: Sale of the complete Neuro20 PRO System including the Smart Suit, Control Box, software, and accessories. The system is sold to healthcare providers for clinical use and directly to patients for home use.
2. Smart Suit Replacement Parts: The Smart Suit has a 6-month warranty and is considered a consumable wearable component. Replacement suits are sold separately to existing customers.
3. Software and Updates: The Neuro20 PRO Software contains programs for various therapeutic applications. Software licensing is bundled with the hardware system.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Core offering

Neuro20 Technologies designs, manufactures, and sells the FDA-cleared Neuro20 PRO System, a whole-body wearable electrophysiological neuromodulation platform consisting of a Smart Suit with 20 contoured electrodes that engage over 42 muscles, a battery-powered Control Box, and tablet-based software with 4 main programs and 9 additional modes. The system is sold to healthcare providers for in-clinic use and directly to patients for home rehabilitation across neurological, orthopedic, chronic pain, and sports performance applications.

Product overview

Neuro20 Technologies offers the Neuro20 PRO System, a comprehensive whole-body wearable neuromuscular stimulation platform consisting of three integrated components: the Neuro20 PRO Smart Suit (a wearable garment with 20 embedded electrodes stimulating 42+ muscles), the Neuro20 PRO Control Box (a battery-powered muscle stimulator), and the Neuro20 PRO Software (tablet-based control application with 4 main programs and 9 additional modes for NMES/FES/PEMS). The system is FDA-cleared for indications including muscle atrophy prevention, muscle re-education, spasm relaxation, increased blood circulation, range of motion improvement, and muscle strength enhancement. The company also offers a Home Care Unit variant for patient self-administration and companion mobile App and Webpanel for system control and monitoring.

Differentiator

Problem solved

Functional benefit

Brands

• Neuro20 PRO: Primary FDA-cleared whole-body wearable neuromuscular stimulation system with smart suit, control box, and software.
• Neuro20 SOLO
• Neuro20 Efficient Health

Products and services

• Neuro20 PRO System FDA-cleared Class II whole-body wearable neuromuscular stimulation system for clinical use by healthcare providers. Recruits Type I and II muscle fibers through 20 large contoured electrodes engaging over 42 muscles for rehabilitation, muscle re-education, spasm relaxation, blood circulation, range of motion, and muscle strength.
• Neuro20 PRO Home Care Unit Home-use version of the Neuro20 PRO System sold directly to patients for at-home rehabilitation, allowing patients to continue therapy and build on clinical results. Available in 7 Smart Suit sizes with sizing guidance for home users.
• Neuro20 PRO Smart Suit (Replacement) Replacement Smart Suit garment sold separately as a consumable component with a 6-month warranty. Wearable garment with 20 large contoured electrodes embedded in fabric that delivers whole-body electrical stimulation.

Quantifiable outcome

• 36% cardiovascular endurance improvement in active group vs control group (G. Bourjeily, 2003 study on device with minimal technological advancements compared to Neuro20)
• +3 more outcomes

Named customers6 records

Segments6 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Three partnerships are on record, tiered core and minor.

• Top Rehabilitation HospitalscoreStrategic or Co-development PartnerNeuro20 is currently working with 8 of the top 25 rehabilitation hospitals nationwide in clinical trials, pilot studies, and hundreds of case studies. These partnerships are conducting IRB-approved research at top institutions around the US.
• University of Tampa Human Performance LabcoreStrategic or Co-development PartnerConducted pilot study demonstrating 9.68 Bone Density and 1.9 Bone Mineral Content Gain compared to control group using Neuro20 technology.
• Together We Walk FoundationminorStrategic or Co-development PartnerNeuro20 partners with Together We Walk, a non-profit devoted to promulgating the health benefits of electro-stimulation. Dr. George Maltezos serves as Executive Director of the WALK foundation.

Scale indicators2 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Helius Medical Technologies: Public neurostimulation company with FDA-cleared Portable Neuromodulation Stimulator (PoNS) for traumatic brain injury and multiple sclerosis rehabilitation. Directly comparable therapeutic positioning in neurorehab and the same target indications Neuro20 addresses with its whole-body EMS approach.
• Restorative Therapies: Maker of the RT300 functional electrical stimulation (FES) cycle and other FES devices for spinal cord injury, MS, and stroke rehabilitation. Same neurological rehab target indications and same core technology category (FES/NMES) sold to clinics and home users.
• miha bodytec: German-based manufacturer of whole-body EMS training systems (i-motion) used in studios, clinics, and rehab settings. Closest architectural peer to Neuro20's 20-electrode whole-body suit concept for fitness, rehab, and performance applications.
• Zynex Medical: Public company selling TENS/EMS and neuromuscular electrical stimulation devices for pain management and rehabilitation. Direct overlap with Neuro20's electrotherapy hardware and consumables business model and reimbursement/clinical positioning.
• BTL Industries: Global aesthetics and rehabilitation device maker selling EMS-based and electromagnetic therapy systems (e.g., Emsculpt, Emsella) into clinics and PT practices. Overlapping customer base (clinics, PTs) and overlapping electrotherapy modality.
• XBody: Whole-body EMS device maker with wearable suits and trainer software, primarily sold into fitness studios and physical therapy clinics. Comparable whole-body EMS architecture and similar split between clinical/performance use cases.
• Compex (DJO / Enovis): Long-established consumer and clinical electrical muscle stimulation (EMS) brand, now owned by Enovis (formerly DJO). Directly comparable product category (NMES/EMS hardware + consumable accessories) sold to athletes, physical therapists, and home users for muscle re-education, recovery, and pain.

Emerging players

• Axiobionics: Niche developer of neuroprosthetic and functional electrical stimulation devices for rehabilitation and movement disorders. Comparable FES/EMS modality focused on neurological rehab in a smaller, emerging player.

Broad incumbents

• Inspire Medical Systems: Established public neurostimulation incumbent ($677M revenue) best known for implanted hypoglossal nerve stimulation for sleep apnea. Comparable FDA-cleared neurostimulation device company in the broader neurotech/neuromodulation category, though focused on implantable rather than external EMS.
• Chattanooga / DJO (Enovis): Major rehabilitation and orthopedic device manufacturer offering a broad portfolio of electrotherapy, ultrasound, and rehab equipment to PT clinics and hospitals under the Chattanooga brand. Comparable product category (PT clinic electrotherapy equipment) sold into the same provider customers, but as part of a much larger portfolio.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/neurotwenty
• YouTubeyoutube.com/@neuro20tech
• Facebookfacebook.com/neurotwenty
• LinkedInlinkedin.com/company/neurotwenty
• Instagraminstagram.com/neurotwenty

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Neuro20 Technologies